clinical trials for glp 1 GLP-1 RAs: summary of head-to-head triple action glp 1 acting

33 There are no randomized kidney outcome trials that examine the effect of combination GLP1RA/SGLT2 inhibitor therapies versus monotherapy

Champeau M, Povoa V, Militao L, Cabrini FM, Picheth GF, Meneau F, Jara CP, de Araujo EP, de Oliveira MG

For GLP-1 RAs, patients aged 018 years showed a notably higher signal intensity for biliary disorder AEs, meeting the thresholds for all four analytical methods

While Glucagon-Like Peptide 1 modulators (or GLP1-RMs) such as those with agonistic mechanisms of action have emerged as effective agents for weight management, MBS remains the most effective intervention for Class II (BMI 3539.9.9) and Class III (BMI 40+) obesity [6]